clinical trials

Researchers call for more pragmatic clinical trials in MS

Few multiple sclerosis (MS) clinical trials have used a so-called pragmatic design, which evaluates the effectiveness of interventions in real-life routine practice, a study has found. Because such trials are better able to emulate conditions in real-world clinical practice and provide solid and more actionable evidence to inform treatment…

EBV-001 vaccine prevents EBV infection in lab-grown human cells

EBV-001, a vaccine candidate being developed by EBViously to target the Epstein-Barr virus (EBV), triggered the production of potent antibodies against the virus in mice, and blood samples from these animals prevented EBV infection in lab-grown human cells. That’s according to new data presented by the company, which is…

Cannabis oral spray nabiximols found to ease spasticity in MS

Treatment with the cannabis oral spray nabiximols helped to relieve spasticity ā€” increased muscle stiffness and spasms common in people with multiple sclerosis (MS) ā€” among participants in two MS clinical trials, according to the results of a new analysis. “In this analysis, nabiximols was shown to significantly…

MS TreatSim Program Allows Simulation of RRMS Clinical Trials

Researchers have created a computer program that can simulate clinical trial responses for relapsing-remitting multiple sclerosis (RRMS), which may improve clinical trial design for novel disease-modifying therapies. The tool, called MS TreatSim,Ā was described in the study, “In silico clinical trials for relapsing-remitting multiple sclerosis…

Expert Voices: Understanding pediatric multiple sclerosis research and care

In this installment of our ā€œExpert Voicesā€ series, Multiple Sclerosis News Today asked Tanuja Chitnis, MD, to answer some of your questions about pediatric multiple sclerosis (MS). Chitnis is a board-certified neurologist specializing in multiple sclerosis-related neuroimmunological disorders. Chitnis’s interest in children with MS led her to create…

Hunt for EBV Vaccine Gets a Boost From NIH

The National Institutes of Health (NIH) is joining the search for a vaccine to attack the Epstein-Barr virus (EBV). This is a big deal for people with multiple sclerosis, because carrying the virus is thought to play a significant role in the development of MS. In fact,…

Crossing the Lemtrada Finish Line

I’m marking a big anniversary this month. It’s been four years since I finished the second round of treatment with Lemtrada (alemtuzumab), my final disease-modifying therapy (DMT). That means that, after about 60 monthly blood draws, I’m finished being stuck. Lemtrada is usually a two-phase series of injections, with…

VISIONARY-MS Trial of CNM-Au8 to End Early Due to Pandemic

VISIONARY-MS, a Phase 2 clinical trial evaluating the safety and effectiveness of CNM-Au8 in people with relapsing multiple sclerosis (MS) with disease-related visual impairment, will conclude early due to COVID-19 pandemic-related challenges. The release of trial data is expected in the second half of this year, according to…

Study Finds Lemtrada Safe for MS Patients With Other Autoimmunity

Other autoimmune conditions, particularly those characterized by the presence of anti-TPO antibodies, should not preclude patients with multiple sclerosis (MS) from receiving treatment with Lemtrada (alemtuzumab), according to an analysis of pooled data from clinical trials and post-market data. The study, ā€œAutoimmunity and long-term safety and efficacy…

1st Patient Enrolled in ENSURE Trials of IMU-838 in RRMS

Immunic TherapeuticsĀ has enrolled the first participant in its Phase 3 ENSURE clinical trial program, which is testing the company’s investigational treatment IMU-838 (vidofludimus calcium) in people with relapsing-remitting multiple sclerosis (RRMS). “Enrollment of the first patient in ENSURE … marks an important inflection point for Immunic as we…

First Patient Dosed in Phase 1 Trial of IMS001 Therapy

ImStem Biotechnology announced that the first patient in its Phase 1 clinical trial for IMS001, an investigational treatment for multiple sclerosis (MS), has been dosed at the Shepherd Center in Atlanta. The trial (NCT04956744) is recruiting participants with an MS diagnosis ages 18 to 65. More information…

CALLIPER Trial for Progressive MS Enrolls First Patient

Immunic Therapeutics has enrolled the first patient in a Phase 2 clinical trial testing its oral therapy candidate IMU-838 for the treatment of progressive multiple sclerosis (MS). The trial, CALLIPER (NCT05054140), is expected to run in parallel to the companyā€™s two identically-designed Phase 3 trials, dubbed…

BioNews Clinical Will Bring Trials Into ‘Continuum’ of MS Care

A new service, BioNews ClinicalĀ is seeking to bring more patients into relevant clinical trials by helping all involved ā€” scientists, pharmaceutical companies, people with diseases ā€” regard these studies as part of continuing care. ā€œToday what happens is that the conversation about patients participating in a clinical trial is…

COVID-19 Vaccine Trial Testing Extra Dose in MS, Other Diseases

A new clinical trial launched by the National Institutes of Health (NIH) is evaluating the impact of an extra dose of an approved or authorized COVID-19 vaccine in people withĀ multiple sclerosis (MS) and other autoimmune diseasesĀ who did not properly respond to an original vaccine regimen. Approximately 600 people will…